Tag Archive : Cruz

/ Cruz

The Law Offices of Frank R. Cruz announces an investigation of Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ: FIXX) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

In June 2019, the Company launched a dose-escalation Phase 1/2 clinical trial for HMI-102, its lead product candidate for the treatment of phenylketonuria. Homology “reported encouraging safety and efficacy data from the dose-escalation portion of the trial” and claimed that the data showed HMI-102 “produced a sustained reduction in phenylalanine (Phe).”

Then, on July 21, 2020, Mariner Research published a report, alleging that the Company’s comments “conveniently ignor[ed] the implications to efficacy and the business.” Citing data from a mouse study, the Phase 1/2 trial, and a key patient’s Facebook posts, the report concluded that HMI-102 “therapy is showing zero efficacy even for a

Read More

The Law Offices of Frank R. Cruz announces an investigation of Fulton Financial Corporation (“Fulton” or the “Company”) (NASDAQ: FULT) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On September 28, 2020, the U.S. Securities and Exchange Commission (“SEC”) announced that Fulton had been charged with accounting and disclosure violations. Specifically, the SEC stated that, in two quarters in which Fulton was on track to meet or beat analyst consensus EPS estimates, Fulton included a valuation allowance that “was at odds” with its reported methodology. Then, in mid-2017, “Fulton belatedly reversed the valuation allowance, increasing its EPS by a penny in a quarter when it otherwise would have fallen short of consensus estimates.”

On this news, the Company’s share price fell sharply during intraday trading on September 29, 2020.

Follow us for

Read More